Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company's segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
Industry, Sector and Symbol:
- Market Cap: $15.1 million
- Outstanding Shares: 6,564,000
- 50 Day Moving Avg: $2.19
- 200 Day Moving Avg: $0.70
- 52 Week Range: $2.14 - $12.80
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 13.53
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $2.07 per share
- Price / Book: 1.11
- EBIDTA: ($16,860,000.00)
- Return on Equity: -291.26%
- Return on Assets: -64.25%
- Debt-to-Equity Ratio: 0.17%
- Current Ratio: 0.07%
- Quick Ratio: 0.07%
- Average Volume: 1.93 million shs.
- Beta: 1.75
- Short Ratio: 4.18
Frequently Asked Questions for Immune Pharmaceuticals (NASDAQ:IMNP)
What is Immune Pharmaceuticals' stock symbol?
Immune Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMNP."
How were Immune Pharmaceuticals' earnings last quarter?
Immune Pharmaceuticals Inc (NASDAQ:IMNP) released its quarterly earnings data on Monday, August, 15th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). View Immune Pharmaceuticals' Earnings History.
Where is Immune Pharmaceuticals' stock going? Where will Immune Pharmaceuticals' stock price be in 2017?
1 equities research analysts have issued twelve-month target prices for Immune Pharmaceuticals' shares. Their forecasts range from $3.00 to $3.00. On average, they expect Immune Pharmaceuticals' share price to reach $3.00 in the next twelve months. View Analyst Ratings for Immune Pharmaceuticals.
Are investors shorting Immune Pharmaceuticals?
Immune Pharmaceuticals saw a increase in short interest in April. As of April 28th, there was short interest totalling 750,273 shares, an increase of 35.8% from the April 13th total of 552,499 shares. Based on an average daily trading volume, of 2,183,226 shares, the short-interest ratio is currently 0.3 days. Currently, 8.5% of the shares of the company are short sold.
Who are some of Immune Pharmaceuticals' key competitors?
Some companies that are related to Immune Pharmaceuticals include HTG Molecular Diagnostics (HTGM), Mirna Therapeutics (MIRN), Aldeyra Therapeutics (ALDX), Sonoma Pharmaceuticals (SNOA), Ocera Therapeutics (OCRX), Marinus Pharmaceuticals (MRNS), Pain Therapeutics (PTIE), Cytori Therapeutics (CYTX), PLx Pharma (PLXP), Vical Incorporated (VICL), Heat Biologics (HTBX), OHR Pharmaceutical (OHRP), Auris Medical Holding AG (EARS), TrovaGene (TROV), CareDx (CDNA), Streamline Health Solutions (STRM), Proteon Therapeutics (PRTO) and Galena Biopharma (GALE).
Who owns Immune Pharmaceuticals stock?
Immune Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (75.91%). Company insiders that own Immune Pharmaceuticals stock include Daniel Gedeon Teper, Daniel Kazado, Monica E Luchi and Rene Pierre Azria. View Institutional Ownership Trends for Immune Pharmaceuticals.
Who bought Immune Pharmaceuticals stock? Who is buying Immune Pharmaceuticals stock?
Immune Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have bought Immune Pharmaceuticals stock in the last two years include Daniel Gedeon Teper, Daniel Kazado, Monica E Luchi and Rene Pierre Azria. View Insider Buying and Selling for Immune Pharmaceuticals.
How do I buy Immune Pharmaceuticals stock?
Shares of Immune Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Immune Pharmaceuticals stock cost?
One share of Immune Pharmaceuticals stock can currently be purchased for approximately $2.30.
Earnings History for Immune Pharmaceuticals (NASDAQ:IMNP)Earnings History by Quarter for Immune Pharmaceuticals (NASDAQ:IMNP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Immune Pharmaceuticals (NASDAQ:IMNP)
Current Year EPS Consensus Estimate: $-0.62 EPS
Next Year EPS Consensus Estimate: $0.17 EPS
Dividend History for Immune Pharmaceuticals (NASDAQ:IMNP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Immune Pharmaceuticals (NASDAQ:IMNP)
Insider Ownership Percentage: 6.74%Insider Trades by Quarter for Immune Pharmaceuticals (NASDAQ:IMNP)
Institutional Ownership Percentage: 2.18%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|1/4/2017||Daniel Kazado||Director||Buy||76,503||$0.19||$14,535.57|| |
|12/16/2016||Daniel Kazado||Director||Buy||161,377||$0.19||$30,661.63|| |
|8/4/2016||Daniel Gedeon Teper||CEO||Buy||937,500||$0.38||$356,250.00|| |
|8/4/2016||Daniel Kazado||Director||Buy||666,667||$0.45||$300,000.15|| |
|8/4/2016||Monica E Luchi||CMO||Buy||777,778||$0.45||$350,000.10|| |
|1/26/2016||Daniel Gedeon Teper||CEO||Buy||42,000||$0.59||$24,780.00|| |
|1/19/2016||Daniel Gedeon Teper||CEO||Buy||44,200||$0.57||$25,194.00|| |
|1/12/2016||Daniel Gedeon Teper||CEO||Buy||39,400||$0.62||$24,428.00|| |
|1/5/2016||Daniel Gedeon Teper||CEO||Buy||62,000||$0.81||$50,220.00|| |
|12/7/2015||Daniel Gedeon Teper||CEO||Buy||65,400||$0.76||$49,704.00|| |
|12/7/2015||Daniel Kazado||Director||Buy||150,000||$0.78||$117,000.00|| |
|10/26/2015||Daniel Gedeon Teper||CEO||Buy||18,400||$1.36||$25,024.00|| |
|10/19/2015||Daniel Gedeon Teper||CEO||Buy||18,600||$1.34||$24,924.00|| |
|10/12/2015||Daniel Gedeon Teper||CEO||Buy||19,000||$1.30||$24,700.00|| |
|10/5/2015||Daniel Gedeon Teper||CEO||Buy||40,700||$1.23||$50,061.00|| |
|9/14/2015||Rene Pierre Azria||Director||Buy||50,000||$1.48||$74,000.00|| |
|9/1/2015||Daniel Gedeon Teper||CEO||Buy||7,569||$1.29||$9,764.01|| |
Headline Trends for Immune Pharmaceuticals (NASDAQ:IMNP)
Latest Headlines for Immune Pharmaceuticals (NASDAQ:IMNP)
Immune Pharmaceuticals (IMNP) Chart for Tuesday, May, 23, 2017